Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

[The Deutsches Rheuma-Forschungszentrum - and German rheumatology].

Schulze-Koops H; den Vorstand der Deutschen Gesellschaft für Rheumatologie.

Z Rheumatol. 2020 Mar;79(2):121-122. doi: 10.1007/s00393-020-00755-w. German. No abstract available.

PMID:
32125508
2.

Altered T cell plasticity favours Th17 cells in early arthritis.

Leipe J, Pirronello F, Schulze-Koops H, Skapenko A.

Rheumatology (Oxford). 2020 Feb 6. pii: kez660. doi: 10.1093/rheumatology/kez660. [Epub ahead of print]

PMID:
32030419
3.

Rheuma jeder Art sicher erkennen.

Schulze-Koops H.

MMW Fortschr Med. 2020 Feb;162(2):34. doi: 10.1007/s15006-020-0102-y. Review. German. No abstract available.

PMID:
32016766
4.

[Characteristic symptoms of inflammatory rheumatic diseases].

Mucke J, Sewerin P, Schneider M, Schulze-Koops H.

MMW Fortschr Med. 2020 Feb;162(2):35-39. doi: 10.1007/s15006-020-0103-x. Review. German. No abstract available.

PMID:
32016765
5.

[Update Giant Cell Arteriitis].

Dechant C, Schulze-Koops H.

Dtsch Med Wochenschr. 2019 Oct;144(20):1432-1436. doi: 10.1055/a-0722-6620. Epub 2019 Oct 8. Review. German.

PMID:
31594019
6.

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts.

Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, Hasler P, Rubbert-Roth A, Schulze-Koops H, Kempis JV.

J Clin Med. 2019 Sep 26;8(10). pii: E1548. doi: 10.3390/jcm8101548.

7.

3D black-blood 3T-MRI for the diagnosis of abdominal large vessel vasculitis.

Maurus S, Sommer NN, Kooijman H, Coppenrath E, Witt M, Schulze-Koops H, Czihal M, Hoffmann U, Saam T, Treitl KM.

Eur Radiol. 2020 Feb;30(2):1041-1044. doi: 10.1007/s00330-019-06432-0. Epub 2019 Sep 16.

PMID:
31529250
8.

Increased plasticity of non-classic Th1 cells toward the Th17 phenotype.

Leipe J, Pirronello F, Klose A, Schulze-Koops H, Skapenko A.

Mod Rheumatol. 2019 Oct 17:1-7. doi: 10.1080/14397595.2019.1667473. [Epub ahead of print]

PMID:
31512538
9.

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR).

Ramos-Casals M, Maria A, Suárez-Almazor ME, Lambotte O, Fisher BA, Hernández-Molina G, Guilpain P, Pundole X, Flores-Chávez A, Baldini C, Bingham Iii CO, Brito-Zerón P, Gottenberg JE, Kostine M, Radstake TRD, Schaeverbeke T, Schulze-Koops H, Calabrese L, Khamashta MA, Mariette X; ICIR.

Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):114-122. Epub 2019 Aug 28.

10.

A Rare Side Effect of Checkpoint Inhibitor Therapy-Nivolumab-Induced Axial Polyarthritis of the Facet and Costovertebral Joints.

Feist J, Murray A, Skapenko A, Schulze-Koops H.

Arthritis Rheumatol. 2019 Nov;71(11):1823. doi: 10.1002/art.41036. Epub 2019 Sep 20. No abstract available.

PMID:
31297971
11.

Ocular ischaemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment.

Czihal M, Tschaidse J, Bernau C, Lottspeich C, Köhler A, Dechant C, Schulze-Koops H, Hoffmann U, Mackert MJ, Thurau S.

Clin Exp Rheumatol. 2019 Mar-Apr;37 Suppl 117(2):61-64. Epub 2019 May 21.

12.
13.

Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).

Dörner T, Schulze-Koops H, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP.

Clin Exp Rheumatol. 2019 Nov-Dec;37(6):937-945. Epub 2019 Apr 16.

14.

Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA.

Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, Schulze-Koops H.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):783-790. Epub 2019 Apr 9.

15.

A complex pattern of autonomic dysfunction in familial Mediterranean fever. Results from a controlled cross-sectional study.

Moog P, Valda K, Eren OE, Rauschel V, Kossegg SJ, Bachmann Q, Schmaderer C, Straube A, Schulze-Koops H, Witt M.

Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 121(6):35-42. Epub 2019 Mar 18.

16.

[Morbus Bechterew - diagnosis and therapy].

Knünz A, Schulze-Koops H.

MMW Fortschr Med. 2019 Mar;161(Suppl 1):61-69. doi: 10.1007/s15006-019-0013-y. Review. German. No abstract available.

PMID:
30912085
17.

Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N.

Arthritis Rheumatol. 2019 Aug;71(8):1329-1338. doi: 10.1002/art.40876. Epub 2019 Jul 3.

19.

The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.

Choy EHS, Miceli-Richard C, González-Gay MA, Sinigaglia L, Schlichting DE, Meszaros G, de la Torre I, Schulze-Koops H.

Clin Exp Rheumatol. 2019 Jul-Aug;37(4):694-704. Epub 2019 Feb 11. Review.

20.

Assessment of Disease Activity in Takayasu Arteritis: Potential Role of Contrast-Enhanced Ultrasound.

Lottspeich C, Dechant C, Köhler A, Tischler M, Treitl KM, Treitl M, Schulze-Koops H, Hoffmann U, Czihal M.

Ultraschall Med. 2019 Oct;40(5):638-645. doi: 10.1055/a-0817-5423. Epub 2019 Jan 23.

PMID:
30674040
21.

Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, Foeldvari I, Föll D, Frosch M, Ganser G, Gaubitz M, Günther A, Heinz C, Horneff G, Huemer C, Kopp I, Lommatzsch C, Lutz T, Michels H, Neß T, Neudorf U, Pleyer U, Schneider M, Schulze-Koops H, Thurau S, Zierhut M, Lehmann HW.

Semin Arthritis Rheum. 2019 Aug;49(1):43-55. doi: 10.1016/j.semarthrit.2018.11.004. Epub 2018 Dec 4. Review.

22.

Diagnostic accuracy of positron emission tomography for assessment of disease activity in large vessel vasculitis.

Schramm N, Ingenhoff J, Dechant C, Treitl KM, Treitl M, Proft F, Schulze-Koops H, Hoffmann U, Bartenstein P, Rominger A, Czihal M.

Int J Rheum Dis. 2019 Aug;22(8):1371-1377. doi: 10.1111/1756-185X.13440. Epub 2018 Nov 22.

PMID:
30565885
23.

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.

Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch MH, Schulze-Koops H, Kucharz EJ, Woehling H, Babic G, Poetzl J, Davis A, Schwebig A.

RMD Open. 2018 Nov 14;4(2):e000757. doi: 10.1136/rmdopen-2018-000757. eCollection 2018.

24.

Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.

Tony HP, Krüger K, Cohen SB, Schulze-Koops H, Kivitz AJ, Jeka S, Vereckei E, Cen L, Kring L, Kollins D.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):88-94. doi: 10.1002/acr.23771.

25.

[Immunology of systemic inflammatory diseases].

Aringer M, Schulze-Koops H.

Orthopade. 2018 Nov;47(11):891-898. doi: 10.1007/s00132-018-3647-z. Review. German.

PMID:
30267123
26.

The Value of an Automated Ultrasound System in the Detection of Synovitis.

Mueller R, Grunke M, Wendler J, Schuch F, Hofmann-Preiss K, Boettger I, Jakobs R, Schulze-Koops H, von Kempis J.

Ultrasound Int Open. 2018 Apr;4(2):E61-E68. doi: 10.1055/a-0612-7852. Epub 2018 Jul 11.

27.

Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy.

Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, Goldscheider I, Kauffmann-Guerrero D, Huber RM, Dechant C, Berking C, Schulze-Koops H, Skapenko A.

RMD Open. 2018 Aug 17;4(2):e000714. doi: 10.1136/rmdopen-2018-000714. eCollection 2018.

28.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

29.

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K.

Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Review. German.

PMID:
29968101
30.

Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort.

Mueller RB, Kaegi T, Haile SR, Schulze-Koops H, Schiff M, von Kempis J.

RMD Open. 2018 Jun 6;4(1):e000673. doi: 10.1136/rmdopen-2018-000673. eCollection 2018.

31.

[Biomarkers and imaging for diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the BMBF consortium ArthroMark].

Häupl T, Skapenko A, Hoppe B, Skriner K, Burkhardt H, Poddubnyy D, Ohrndorf S, Sewerin P, Mansmann U, Stuhlmüller B, Schulze-Koops H, Burmester GR.

Z Rheumatol. 2018 May;77(Suppl 1):16-23. doi: 10.1007/s00393-018-0458-x. Review. German.

PMID:
29691690
32.

Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort.

Heinimann K, von Kempis J, Sauter R, Schiff M, Sokka-Isler T, Schulze-Koops H, Müller R.

J Clin Med. 2018 Mar 13;7(3). pii: E57. doi: 10.3390/jcm7030057.

33.

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.

Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22.

34.

[Revised version of the statement by the DGRh on biosimilars-update 2017].

Braun J, Lorenz HM, Müller-Ladner U, Schneider M, Schulze-Koops H, Specker C, Strangfeld A, Wagner U, Dörner T.

Z Rheumatol. 2018 Feb;77(1):81-90. doi: 10.1007/s00393-017-0407-0. German.

PMID:
29383440
35.

[Paraneoplastic syndromes in rheumatology].

Leipe J, Schulze-Koops H.

Internist (Berl). 2018 Feb;59(2):145-150. doi: 10.1007/s00108-017-0376-z. Review. German.

PMID:
29340740
36.

Relapses in three patients with Takayasu arteritis under tocilizumab treatment detected by contrast enhanced ultrasound.

Czihal M, Lottspeich C, Schröttle A, Treitl KM, Treitl M, Leipe J, Schulze-Koops H, Hoffmann U, Dechant C.

Vasa. 2018 Feb;47(2):149-152. doi: 10.1024/0301-1526/a000679. Epub 2017 Dec 22.

37.

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K.

Rheumatology (Oxford). 2018 Mar 1;57(3):589. doi: 10.1093/rheumatology/kex503. No abstract available.

38.

Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Kalden JR, Schulze-Koops H.

Nat Rev Rheumatol. 2017 Nov 21;13(12):707-718. doi: 10.1038/nrrheum.2017.187. Review.

PMID:
29158574
39.

Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.

Schulze-Koops H, Skapenko A.

Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv30-iv48. doi: 10.1093/rheumatology/kex277. Review.

40.

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.

Schulze-Koops H.

Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv1-iv3. doi: 10.1093/rheumatology/kex275. No abstract available.

41.

Pupillary autonomic dysfunction in patients with ANCA-associated vasculitis.

Moog P, Eren O, Kossegg S, Valda K, Straube A, Grünke M, Schulze-Koops H, Witt M.

Clin Auton Res. 2017 Dec;27(6):385-392. doi: 10.1007/s10286-017-0463-1. Epub 2017 Sep 1.

PMID:
28864843
42.

Trial of Tocilizumab in Giant-Cell Arteritis.

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N.

N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849.

43.

[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T.

Z Rheumatol. 2018 Feb;77(1):28-39. doi: 10.1007/s00393-017-0330-4. German.

PMID:
28589389
44.

[Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases : Experiences from a German registry (GRAID2)].

Proft F, Fleck M, Fiehn C, Schulze-Koops H, Witt M, Dörner T, Henes JC.

Z Rheumatol. 2018 Feb;77(1):46-54. doi: 10.1007/s00393-017-0329-x. German.

PMID:
28589388
45.

[Rituximab for the treatment of poly- and dermatomyositis : Results from the GRAID-2 registry].

Fiehn C, Unger L, Schulze-Koops H, Proft F, Henes JC, Jacobi A, Dörner T.

Z Rheumatol. 2018 Feb;77(1):40-45. doi: 10.1007/s00393-017-0327-z. German.

PMID:
28536935
46.

[Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)].

Henes JC, Schulze-Koops H, Witt M, Tony HP, Mueller F, Grunke M, Czihal M, Dörner T, Proft F.

Z Rheumatol. 2018 Feb;77(1):12-20. doi: 10.1007/s00393-017-0325-1. German.

PMID:
28536934
47.

[Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)].

Venhoff N, Proft F, Schulze-Koops H, Holle J, Voll RE, Iking-Konert C, Jacobi AM, Henes J, Unger L, Kneitz O, Dörner T, Thiel J.

Z Rheumatol. 2018 Feb;77(1):21-27. doi: 10.1007/s00393-017-0315-3. German.

PMID:
28508096
48.

Defining Epigenetic Regulation of the Interleukin-9 Gene by Chromatin Immunoprecipitation.

Skapenko A, Schulze-Koops H.

Methods Mol Biol. 2017;1585:179-187. doi: 10.1007/978-1-4939-6877-0_14.

PMID:
28477196
49.

[A Blocked Frontal Sinus with Orbital Swelling].

Ledderose GJ, Schulze-Koops H, Link V.

Laryngorhinootologie. 2017 Mar;96(3):180-182. doi: 10.1055/s-0043-103277. Epub 2017 Apr 18. German. No abstract available.

PMID:
28420023
50.

B-mode sonography wall thickness assessment of the temporal and axillary arteries for the diagnosis of giant cell arteritis: a cohort study.

Czihal M, Schröttle A, Baustel K, Lottspeich C, Dechant C, Treitl KM, Treitl M, Schulze-Koops H, Hoffmann U.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):128-133. Epub 2017 Apr 4.

PMID:
28375835

Supplemental Content

Loading ...
Support Center